Mason Carrico
Stock Analyst at Stephens & Co.
(1.75)
# 3,142
Out of 4,883 analysts
77
Total ratings
30.56%
Success rate
-9.58%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Reiterates: Overweight | $67 | $41.57 | +61.19% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $100.66 | +4.31% | 8 | May 20, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $1.8 | $1.48 | +22.03% | 5 | May 15, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $12.76 | +9.76% | 6 | May 15, 2025 | |
| HOLX Hologic | Maintains: Overweight | $77 → $70 | $65.26 | +7.26% | 4 | May 13, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $19.48 | +105.34% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $104.10 | +10.47% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $27.69 | +62.51% | 7 | Mar 26, 2025 | |
| GH Guardant Health | Reiterates: Overweight | $55 | $51.28 | +7.25% | 5 | Mar 26, 2025 | |
| AKYA Akoya Biosciences | Downgrades: Equal-Weight | $3.5 → $1.8 | $1.38 | +30.91% | 6 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $3.65 | +64.38% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $17.57 | -3.24% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $44.07 | +17.99% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $5.67 | +252.73% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $20.22 | +102.77% | 7 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 | $159.72 | -21.74% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 | $7.41 | +156.41% | 1 | Jul 30, 2024 |
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $41.57
Upside: +61.19%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $100.66
Upside: +4.31%
Pacific Biosciences of California
May 15, 2025
Reiterates: Overweight
Price Target: $1.8
Current: $1.48
Upside: +22.03%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $12.76
Upside: +9.76%
Hologic
May 13, 2025
Maintains: Overweight
Price Target: $77 → $70
Current: $65.26
Upside: +7.26%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $19.48
Upside: +105.34%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $104.10
Upside: +10.47%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $27.69
Upside: +62.51%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $51.28
Upside: +7.25%
Akoya Biosciences
Mar 25, 2025
Downgrades: Equal-Weight
Price Target: $3.5 → $1.8
Current: $1.38
Upside: +30.91%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.65
Upside: +64.38%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $17.57
Upside: -3.24%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $44.07
Upside: +17.99%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $5.67
Upside: +252.73%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $20.22
Upside: +102.77%
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $159.72
Upside: -21.74%
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $7.41
Upside: +156.41%